Literature DB >> 12057099

Brain metastases.

M G Ewend1, L A Carey, D E Morris, R D Harvey, T A Hensing.   

Abstract

Metastatic tumors to the brain are an increasing cause of morbidity and mortality in patients with systemic cancers. Many new therapies used to treat systemic cancers do not penetrate the central nervous system (CNS) and do not protect patients from the development of brain metastases. Surgery, radiosurgery, and radiation therapy are all used to treat brain metastases. It is in our opinion a mistake to use only one or two of these modalities to the exclusion of other(s). The role of systemic chemotherapy is still limited, due to both the issues of drug delivery caused by the blood brain barrier and to the relative resistance of many of these tumors to chemotherapy. Traditionally, brain metastases have been grouped together regardless of the origin of the tumor and have been treated with a single algorithm. As we encounter more patients for whom treatment of the brain metastases is an important determinant of survival, we must tailor our treatment strategies to individual tumor types. Also, we must recognize differences in each tumor's sensitivity to chemotherapy and radiotherapy and differences in their biology.

Entities:  

Mesh:

Year:  2001        PMID: 12057099     DOI: 10.1007/s11864-001-0075-8

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  31 in total

1.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

Authors:  A Aupérin; R Arriagada; J P Pignon; C Le Péchoux; A Gregor; R J Stephens; P E Kristjansen; B E Johnson; H Ueoka; H Wagner; J Aisner
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

2.  Isolated/primary CNS relapse in women in remission after ABMT for metastatic breast cancer.

Authors:  E D Ellis; S F Williams
Journal:  Bone Marrow Transplant       Date:  1992-02       Impact factor: 5.483

3.  Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.

Authors:  C Christodoulou; D Bafaloukos; P Kosmidis; E Samantas; A Bamias; P Papakostas; A Karabelis; C Bacoyiannis; D V Skarlos
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

4.  Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy.

Authors:  J Y Pierga; B Asselain; M Jouve; V Diéras; M Carton; V Laurence; V Girre; P Beuzeboc; T Palangié; T Dorval; P Pouillart
Journal:  Cancer       Date:  2001-03-15       Impact factor: 6.860

5.  Survival of patients with synchronous brain metastases: an epidemiological study in southeastern Michigan.

Authors:  A J Thomas; J P Rock; C C Johnson; L Weiss; G Jacobsen; M L Rosenblum
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

6.  Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients.

Authors:  M Wroński; E Arbit
Journal:  J Neurosurg       Date:  2000-07       Impact factor: 5.115

7.  Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

Authors:  J H Sampson; J H Carter; A H Friedman; H F Seigler
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

8.  Brain metastases as the only manifestation of an undetected primary tumor.

Authors:  L N Nguyen; M H Maor; M J Oswald
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

9.  Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC).

Authors:  R Komaki; C B Scott; R Byhardt; B Emami; S O Asbell; A H Russell; M Roach; M B Parliament; L E Gaspar
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-09-01       Impact factor: 7.038

10.  Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991.

Authors:  M Wroński; E Arbit; M Burt; J H Galicich
Journal:  J Neurosurg       Date:  1995-10       Impact factor: 5.115

View more
  6 in total

1.  Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents.

Authors:  Jane W Marsh; Maryann Donovan; Dennis R Burholt; Lisa D George; Paul L Kornblith
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

Review 2.  Brain metastasis from ovarian cancer: a systematic review.

Authors:  Shabnam Pakneshan; Damoun Safarpour; Fattaneh Tavassoli; Bahman Jabbari
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

3.  Brain metastases from colorectal carcinoma: prognostic factors and outcome.

Authors:  Minkyu Jung; Joong Bae Ahn; Jong Hee Chang; Chang Ok Suh; Soojung Hong; Jae Kyung Roh; Sang Joon Shin; Sun Young Rha
Journal:  J Neurooncol       Date:  2010-05-14       Impact factor: 4.130

4.  Surgical treatment for brain metastases: prognostic factors and survival in 177 patients.

Authors:  Andreas M Stark; Hauke Tscheslog; Ralf Buhl; Janka Held-Feindt; H Maximilian Mehdorn
Journal:  Neurosurg Rev       Date:  2004-12-18       Impact factor: 3.042

Review 5.  Brain metastasis from ovarian cancer: case report and review of the literature.

Authors:  Xi-Quan Hu; Jaime Imitola; Ryan Y Kim; Ali Mahta; Santosh Kesari
Journal:  Med Oncol       Date:  2011-03-06       Impact factor: 3.064

6.  In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis.

Authors:  Avital Gaziel-Sovran; Iman Osman; Eva Hernando
Journal:  Front Oncol       Date:  2013-05-31       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.